Hansa Biopharma Expands Leadership Team to Enhance Growth Strategy and Operations

Hansa Biopharma's Growth Strategy: New Executive Appointments

In a significant move to strengthen its leadership, Hansa Biopharma AB, renowned for its pioneering work in biopharmaceuticals, has announced three key appointments, aimed at facilitating sustained growth and operational excellence. The company, which is traded on Nasdaq Stockholm under the ticker HNSA, is on a mission to provide innovative solutions for patients suffering from rare immunological disorders. The latest additions to their executive team include Brian Gorman as Chief Legal Officer, Sandra Frithiof as Chief Human Resources Officer (CHRO), and Kerstin Falck Lagercrantz as Vice President of Corporate Affairs.

Key Appointments Announced

Starting from August 4, Brian Gorman will assume the role of Chief Legal Officer. With over 20 years of extensive legal experience, Gorman has notably served as Chief Legal Officer at Sinclair Pharma Ltd., where he played a pivotal role in advancing the company’s global expansion strategies. His previous tenure includes significant positions at Calliditas Therapeutics, Opiant Pharmaceuticals, Endo Pharmaceuticals, and AstraZeneca. Gorman began his illustrious career at the international law firm Cleary Gottlieb Steen & Hamilton and holds degrees from Gettysburg College and Villanova University School of Law.

Joining the leadership team concurrently is Sandra Frithiof, who carries more than 25 years of diverse human resources experience. Frithiof comes from Ayvens Sweden AB, a global mobility sector leader, where she held the position of HR Director. At Calliditas Therapeutics, she notably established the Global HR framework to support the company's expansion into the U.S. market. Her past experiences also include influential HR roles at Ramberg Advokater, Karolinska University Hospital, and UTC. She possesses a bachelor’s degree in human resource management from Örebro University in Sweden.

Kerstin Falck Lagercrantz will join the company on September 1, bringing more than two decades of corporate affairs expertise from Pfizer AB. Her leadership between 2014 and 2022 as Corporate Affairs Director included managing external communications and patient engagement, particularly during the COVID-19 pandemic when her efforts influenced healthcare policies significantly. Falck Lagercrantz has also participated in various capacities with SwedenBIO and LIF, showing her commitment to the pharmaceutical industry. She earned her Bachelor of Science in Business Administration and Economics from Uppsala University, Sweden.

A Strategic Vision for the Future

Hansa Biopharma’s CEO, Renée Aguiar-Lucander, expressed enthusiasm about the new appointments, stating, “We are very pleased to welcome Brian, Sandra, and Kerstin to Hansa. They bring invaluable experience in their respective areas of expertise, which will be critical as we step up our US pre-commercial activities.” With the company gearing up for important Phase 3 data readouts and submitting their first Biologics License Application (BLA), the leadership team's experience will play a crucial role in guiding Hansa through these pivotal milestones, bolstering its growth trajectory.

Hansa Biopharma stands out as a leader in biopharmaceutical innovation, particularly with its developed IgG-cleaving enzyme technology platform aimed at treating complex autoimmune diseases. The firm’s flagship product, imlifidase, represents a groundbreaking immunoglobulin G (IgG) antibody-cleaving enzyme therapy that facilitates kidney transplants in highly sensitized patients. Additionally, Hansa is actively developing HNSA-5487, a next-generation IgG-cleaving molecule with potential for repeat dosing.

Given the recent executive changes, Hansa Biopharma is well-positioned to enhance its operational capabilities, ensuring that it meets the needs of patients with rare immunological conditions more effectively. As the company continues to expand its horizon in both European and U.S. markets, stakeholders are optimistic about the future, anticipating significant advancements that Hansa will bring to the biopharmaceutical field.

For further information, please contact Evan Ballantyne, Chief Financial Officer at Hansa Biopharma, at [redacted].

About Hansa Biopharma

Hansa Biopharma AB is a pioneering biopharmaceutical company based in Lund, Sweden, committed to developing innovative treatments that make a difference in the lives of patients with rare immunological diseases. With an extensive portfolio enhanced by its cutting-edge research and development initiatives, Hansa Biopharma is actively transforming patient care through groundbreaking biopharmaceutical innovations. To learn more about Hansa Biopharma and its offerings, visit www.hansabiopharma.com or follow the company on LinkedIn.